Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Impact of Nebivolol on Central Aortic Pressure

This study has been withdrawn prior to enrollment.
(Similar study already published)
Sponsor:
Information provided by:
Creighton University
ClinicalTrials.gov Identifier:
NCT01051947
First received: January 19, 2010
Last updated: July 29, 2011
Last verified: July 2011

January 19, 2010
July 29, 2011
December 2009
May 2010   (final data collection date for primary outcome measure)
Stable blood pressure [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Subjects will be randomized to nebivolol or metoprolol. Their medication will be titrated so that their blood pressure is within 10% of their initial reading.
Not Provided
Complete list of historical versions of study NCT01051947 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Impact of Nebivolol on Central Aortic Pressure
Impact of Nebivolol on Central Aortic Pressure

A randomized, cross-over, single-blind study to compare the effects of nebivolol and metoprolol on central aortic pressure and peripheral brachial pressure in patients with stable cardiovascular disease.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Central Aortic Pressure
  • Drug: Nebivolol
    10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks
  • Drug: Metoprolol
    dosage prescribed prior to starting on study
  • Experimental: Nebivolol
    Nebivolol therapy for 2-6 weeks depending on blood pressure readings
    Intervention: Drug: Nebivolol
  • Experimental: Metoprolol
    Metoprolol therapy for 2-6 weeks depending on blood pressure readings
    Intervention: Drug: Metoprolol
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
May 2010
May 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects with history of hypertension
  • Subjects who have received metoprolol for a minimum of 3 months

Exclusion Criteria:

  • Patients who have had an acute myocardial infarction, coronary revascularization or who have been hospitalized for heart failure or cardiac arrhythmia in the past 6 months
Both
45 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01051947
08-15168
No
Jennifer Campbell, PharmD, Creighton University
Creighton University
Not Provided
Principal Investigator: Jennifer Campbell, PharmD Creighton University
Creighton University
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP